On August 21, the final results of the ADIUVO trial were published online in The Lancet Diabetes & Endocrinology.
ADIUVO is the first randomized trial to assess the efficacy and safety of adjuvant mitotane treatment in patients with completely resected adrenocortical carcinoma (ACC). The ADIUVO trial was an independent, investigator-initiated study supported by public funding and endorsed by the European Network for the Study of Adrenal Tumours (ENSAT). The study was the result of a tremendous effort of the ENSAT community. Despite limited funding, the trial was done in 23 ENSAT centers across 7 countries thanks to the passion and commitment of many people.
ACC Support UK has written a lay summary of the ADIUVO trial article to help patients understand its significance.